{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-342336","form_type":"8-K","ticker":"ENTA","cik":"0001177648","company_name":"ENANTA PHARMACEUTICALS INC","filed_at":"2026-08-10T20:05:18+00:00","discovered_at":"2026-08-10T20:07:01.470364+00:00","generated_at":"2026-08-10T20:08:52.840795+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Enanta Q3 FY26 net loss $19.5M; cash $211.5M; RSV and immunology programs on track","bullets":["Revenue $14.4M from MAVYRET royalties, down from $18.3M YoY; net loss $19.5M ($0.67/sh) vs $18.3M ($0.85/sh).","Cash and marketable securities $211.5M; runway into fiscal 2029; OMERS gets 54.5% of royalties through 2032.","Dosing started in LOTUS Phase 2b pediatric RSV trial of zelicapavir; topline expected 2027; RESOLVE to initiate in 4Q 2026.","EDP-978 Phase 1 topline data expected 4Q 2026; EPS-3903 IND filing targeted 2H 2026; MRGPRX2 candidate selection 2H 2026.","Federal Circuit affirmed invalidity of Pfizer patent; Enanta filed rehearing petition; UPC hearing set for Sept 29, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-342336","json":"https://secwatch.observer/filing/0001193125-26-342336.json","markdown":"https://secwatch.observer/filing/0001193125-26-342336.md","text":"https://secwatch.observer/filing/0001193125-26-342336.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1177648/000119312526342336/0001193125-26-342336-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1177648/000119312526342336/enta-20260810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-10T20:08:52.840795+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}